Efficacy and Safety of Clarithromycin versus Josamycin in the Treatment of Hospitalized Patients with Bacterial Pneumonia
- 1 March 1990
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 18 (2), 164-170
- https://doi.org/10.1177/030006059001800211
Abstract
The efficacy and safety of 500 mg clarithromycin and 1000 mg josamycin both given twice daily for a maximum of 14 days were compared in the treatment of 72 hospitalized patients with bacterial pneumonia. The predominant pathogens isolated were Streptococcus pneumoniae and Staphylococcus aureus. Clinical success was reported for 91.5% of patients treated with clarithromycin and for 87.0% of those treated with josamycin. Eradication of the causative pathogen was noted in 85.7% of patients receiving clarithromycin and in 90% of those receiving josamycin. Adverse events considered probably to relate to therapy were experienced by 2% of patients treated with clarithromycin and by 12.5% of those treated with josamycin; one patient treated with josamycin was withdrawn because of severe nausea and moderate vomiting. Treatment with clarithromycin at half the dosage of josamycin was found to have comparable efficacy and to be associated with a lower incidence of adverse events.This publication has 10 references indexed in Scilit:
- Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in ratsAntimicrobial Agents and Chemotherapy, 1989
- In vitro immunosuppressive properties of spergualins to murine T cell response.The Journal of Antibiotics, 1989
- Comparative in vitro activities of new 14-, 15-, and 16-membered macrolidesAntimicrobial Agents and Chemotherapy, 1988
- The macrolide revival: Thirty five years after erythromycinAntimicrobic Newsletter, 1987
- In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1987
- Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1987
- In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycinAntimicrobial Agents and Chemotherapy, 1987
- In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolideAntimicrobial Agents and Chemotherapy, 1986
- Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A.The Journal of Antibiotics, 1984
- In Vitro Susceptibility Studies with Josamycin and ErythromycinAntimicrobial Agents and Chemotherapy, 1976